Table 4. Univariate and multivariate analysis results for progression-free survival.

PFS: Progression-free survival, ECOG: Eastern Cooperative Oncology Group

Variable	Univariate analysis			Multivariate analysis
	Median PFS (months)	p-value		HR, (95 % CI)	p-value
Age (years)	9.6 vs. 8.9	0.815
<60 vs. ≥60
Sex	9.8 vs. 8.9	0.526
Female vs. Male
ECOG performance status	15.3 vs. 5.9	0.007		0.41, (0.20-0.82)	0.016
0-1 vs. 2
Number of metastatic sites	10.3 vs. 7.9	0.312
Single vs. multiple
Bone metastasis	8.9 vs. 9.8	0.824
Yes vs. No
Liver metastasis	3.4 vs. 10.3	0.021		0.52, (0.24-1.14)	0.125
Yes vs. No
Lung metastasis	8.0 vs. 9.9	0.412
Yes vs. No
Pre-nivolumab	5.3 vs. 10.3	0.021		0.44, (0.22-0.91)	0.029
Sunitinib vs. pazopanib